TMAO Nutrition and Fasting Impact: Normal Range, Diet, and Cardiovascular Risk

What TMAO is, and why it shows up on a cardiovascular panel

Trimethylamine N-oxide (TMAO) is a small, water-soluble compound. It is not itself a nutrient or a drug. Gut bacteria metabolize dietary choline, phosphatidylcholine (found in eggs and organ meats), L-carnitine (concentrated in red meat), and betaine into trimethylamine (TMA). The liver enzyme flavin monooxygenase 3 (FMO3) then oxidizes TMA into TMAO, which circulates in plasma and is cleared by the kidneys.

Fish is a partial exception. Ocean fish contain preformed TMAO in their muscle tissue as an osmoregulatory compound, so eating fish can raise plasma TMAO directly, without needing bacterial conversion first. This is one reason fasting status and recent food intake matter more for TMAO than for many routine cardiovascular labs.

TMAO entered mainstream cardiovascular research through cohort studies in the early 2010s associating higher circulating TMAO with a higher rate of major adverse cardiovascular events in people undergoing cardiac evaluation. That body of observational work is genuinely influential in preventive cardiology and metabolomics research. It has not, as of this writing, translated into an FDA-cleared diagnostic threshold, a Pooled Cohort Equations input, or a formal AHA-endorsed treatment target. Readers should hold both facts at once: the association is real and widely cited, and the clinical action threshold is still a matter of expert opinion rather than regulatory or guideline consensus.

What counts as a normal or optimal TMAO level

Commercial and specialty laboratories generally report an upper limit of roughly 6 micromolar for fasting plasma TMAO, based on population distributions in Western cohorts rather than a validated safety cutoff. Some longevity-oriented practices use a lower target, often cited as under 3 micromolar, extrapolated from the lower end of population ranges rather than from an interventional trial showing that hitting that number changes outcomes.

Multiple prospective cohort studies, most notably a widely cited 2013 analysis of patients undergoing elective cardiac evaluation, found that people in the highest range of fasting TMAO had a meaningfully higher rate of cardiovascular events over follow-up than people in the lowest range, independent of traditional risk factors such as LDL cholesterol and blood pressure. Because the specific identifiers and exact hazard ratios attached to individual studies in earlier drafts of this article could not be verified against the primary literature, this article states the direction and general magnitude of the finding (a meaningfully elevated, not marginal, relative risk) without repeating an unverified precise multiplier. A reviewer with direct database access should confirm exact effect sizes before they are published as fixed numbers.

Fasting plasma TMAO below roughly 6 micromolar is generally considered within the common laboratory range, higher TMAO has been associated with greater cardiovascular event rates in observational cohorts, and no regulatory body or major cardiology society has yet defined an evidence-based treatment threshold; a TMAO result is best interpreted as one contextual data point alongside standard lipid and inflammatory markers, not as a standalone diagnosis.

Age and reduced kidney function push TMAO upward independent of diet, so an elevated result in an older adult or anyone with reduced eGFR should prompt a look at renal function before it is attributed to diet alone.

Does diet reliably change TMAO, and does that change matter clinically

Diet is the most consistently demonstrated modifiable input to TMAO. Multiple controlled feeding studies have shown that diets high in red meat produce higher fasting TMAO than diets matched for protein but built around white meat, fish, or plant protein, and that switching away from red meat lowers fasting TMAO within a few weeks in most participants. Vegetarians and vegans consistently show lower fasting TMAO than omnivores in cross-sectional comparisons. These diet-TMAO relationships are reasonably well established.

What is not established is whether lowering TMAO through diet produces cardiovascular benefit beyond what the diet change itself provides through other pathways, such as reduced saturated fat, reduced sodium, or increased fiber. No randomized trial has tested "lower your TMAO" as a treatment target with cardiovascular events as the outcome. TMAO may be a genuine causal contributor to atherosclerosis, a marker that tracks with other risk-raising dietary patterns, or some mixture of both. Readers should not treat a falling TMAO number as proof that cardiovascular risk has fallen; it is one plausible signal among several, and eating less red meat and more fiber is a reasonable choice on general cardiovascular grounds independent of what it does to a TMAO number.

Eggs are a dense source of dietary choline, and short-term feeding studies have shown that whole eggs raise TMAO within hours in a way that depends on gut bacteria being present. Fish raises plasma TMAO directly through preformed TMAO in the tissue, and that rise is usually short-lived, generally resolving within about half a day. Because fatty fish also carries independent cardiovascular benefits from omega-3 fatty acids, avoiding fish specifically to lower a TMAO number is not supported by the evidence and could work against overall cardiovascular health; avoiding fish only before a scheduled blood draw is the more defensible approach.

How fasting status affects the number on your lab report

TMAO is not stored, so a plasma level mostly reflects recent substrate intake plus ongoing bacterial production, not a stable trait. A meal containing red meat, eggs, or fish can raise TMAO for several hours. A sample drawn shortly after such a meal can look substantially higher than a person's habitual baseline.

Practical implications for testing:

• Fast at least 8, ideally 12, hours before a TMAO blood draw. Water is fine.
• Avoid red meat, eggs, and fish for roughly 24 hours before the draw to reduce the chance of a transient spike being mistaken for a habitual level.
• Note recent antibiotic use and any probiotic or prebiotic supplementation on the requisition. Antibiotics can suppress gut bacteria and temporarily depress TMAO in a way that does not reflect a durable change; TMAO typically rebounds within weeks as the microbiome recovers, and using antibiotics deliberately to lower TMAO is not a recommended strategy.

Extended fasting or intermittent fasting protocols sustained over several weeks have been reported in small studies to lower fasting TMAO, plausibly through both reduced substrate availability and shifts in microbial composition. Time-restricted eating that compresses the eating window without changing food choices has not reliably shown the same effect; eating the same red-meat-heavy meals in a shorter window does not appear to lower TMAO on its own.

Why the same meal produces different TMAO levels in different people

Gut microbial composition is the variable that explains most of the person-to-person variability in TMAO response to identical meals. Certain bacterial groups, including species within Clostridiales and Prevotella, carry the enzymatic machinery (TMA lyases) needed to convert dietary choline and carnitine into TMA efficiently. People with higher abundance of these organisms convert a given meal into more TMA, and therefore more TMAO, than people with lower abundance. This is a documented mechanism in microbiome research, though the precise fold-difference reported in any individual study should be checked against the primary paper before being quoted as a fixed figure.

Strategies aimed at the microbiome rather than the diet substrate itself are less mature. Small trials of multi-strain probiotics and of fiber-forward diets have reported reductions in fasting TMAO, and animal studies of a TMA-lyase inhibitor found in balsamic vinegar and olive oil (3,3-dimethyl-1-butanol) have shown reduced TMAO and reduced atherosclerotic plaque in mouse models. Human trials of that compound as a therapeutic have not, to our knowledge, been completed. Readers should treat probiotic and supplement claims for TMAO reduction as early-stage evidence, not established therapy.

Kidney function changes what a TMAO result means

TMAO is cleared by the kidneys. Reduced kidney function raises TMAO independent of diet, because clearance fails even when production is normal. In patients with more advanced chronic kidney disease, TMAO levels can run many times higher than in people with normal kidney function, and elevated TMAO in that population has been associated with higher mortality in observational data, even after adjusting for kidney function itself. This means a single elevated TMAO value should always be interpreted alongside eGFR. The same TMAO number carries different meaning in someone with normal kidney function than in someone with reduced eGFR, and no separate eGFR-adjusted reference range is yet standardized across laboratories.

Medications and supplements that affect TMAO

• Antibiotics can sharply suppress TMAO by reducing TMA-producing bacteria, but this is a research tool for isolating mechanism, not a treatment strategy, and TMAO rebounds after the microbiome recovers.
• Metformin has been reported in some analyses to associate with modestly lower TMAO, plausibly through effects on gut microbial composition rather than glycemic control itself. This should be read as an observed association in diabetes cohorts, not a reason to start metformin for TMAO reduction.
• Resveratrol and quercetin inhibit FMO3 in laboratory studies, which would theoretically reduce TMAO, but human evidence is limited and effect sizes are small. Neither should be used specifically to lower TMAO outside of a clinician's guidance.

What is established, what is plausible, and what is not established

Established: TMAO is produced through a gut-bacteria-to-liver pathway from dietary choline, carnitine, and betaine. Diets high in red meat and eggs raise fasting TMAO; plant-based diets are associated with lower fasting TMAO. Reduced kidney function raises TMAO independent of diet. Multiple observational cohorts have found an association between higher TMAO and higher cardiovascular event rates.

Plausible but not proven: That TMAO is a direct causal driver of atherosclerosis in humans, rather than a marker that co-travels with other risk-raising dietary and metabolic patterns. That probiotic, prebiotic, or supplement-based microbiome interventions produce durable, clinically meaningful TMAO reduction. That extended fasting protocols produce lasting TMAO reduction beyond the study period.

Not established: A validated, guideline-endorsed TMAO treatment threshold. Evidence from a randomized trial that deliberately lowering TMAO reduces cardiovascular events. Sex-specific or standardized age-specific reference ranges. An eGFR-adjusted interpretation standard across laboratories.

A decision framework for interpreting and acting on a TMAO result

This framework is intended to help a reader and their clinician decide what a TMAO result should and should not change, given the current evidence.

Step 1: Check the draw conditions before trusting the number. Was the sample fasting (8-12 hours)? Was red meat, egg, or fish intake avoided for roughly 24 hours before the draw? If not, the result may be transiently elevated and is not a reliable baseline. Repeat under controlled conditions before acting on it.

Step 2: Check kidney function alongside the TMAO value. A TMAO result should not be interpreted in isolation from eGFR. If eGFR is reduced, an elevated TMAO may reflect impaired clearance rather than diet, and the corrective lever is different (nephrology-guided management, not dietary substrate restriction alone).

Step 3: Separate "this number is common" from "this number is safe." A result within the common laboratory range (roughly under 6 micromolar) is typical, not automatically protective. A result above that range is worth reviewing with a clinician, not an automatic signal of disease. Neither number, on its own, changes a diagnosis.

Step 4: If diet change is the goal, expect the mechanism-supported levers, not a guaranteed clinical outcome. Reducing red meat and egg yolk intake, increasing dietary fiber, and favoring fish and plant protein over red meat are changes with reasonable mechanistic and observational support for lowering fasting TMAO and for general cardiovascular health. Treat a falling TMAO number as a marker of adherence to that diet change, not as independent proof of reduced cardiovascular risk.

Step 5: Do not lean on unproven interventions as a primary strategy. Probiotic strains, DMB-containing foods such as balsamic vinegar and olive oil, and extended fasting protocols have early or animal-stage support. They are reasonable adjuncts within an otherwise sound diet, not substitutes for established cardiovascular risk management (statins or other lipid therapy when indicated, blood pressure control, smoking cessation, and standard ASCVD risk assessment).

Step 6: Know when to escalate. A persistently elevated TMAO despite sustained dietary change, especially alongside other elevated cardiovascular biomarkers (LDL-C, ApoB, Lp(a), hsCRP) or reduced eGFR, is a reasonable trigger to involve a preventive cardiologist or nephrologist rather than to keep adjusting diet alone. TMAO is not, by itself, an indication for starting a prescription medication.

Getting a reliable result

• Fast 8-12 hours before the draw; water is permitted.
• Avoid red meat, eggs, and fish for about 24 hours before the draw.
• Report recent antibiotic use and any probiotic or prebiotic supplements to the ordering clinician, since these can transiently affect the result.
• Ask whether eGFR was checked in the same panel, since kidney function materially changes how a TMAO value should be interpreted.
• If TMAO is being used to track a diet change, repeat testing under matched fasting and pre-draw conditions each time to make comparisons meaningful.

Common questions

References

1. American Heart Association. 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2021. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001031

Other studies referenced in earlier versions of this article (on TMAO and cardiovascular risk, red meat feeding trials, gut bacterial TMA lyase genes, probiotic trials, and CKD cohorts) are widely cited in the TMAO research literature, but the specific identifiers attached to them in the prior draft could not be verified against the primary papers and have been removed pending confirmation by a clinical reviewer with database access. Precise effect sizes in this article have been stated qualitatively rather than as fixed numbers for that reason.